Physician profile
Leigha Fox
NPI 1376125138
$1,066.84
in general payments reported to CMS, 2019-2025
13 companies · $711 in 2025
The $711 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.27 · 2022: $13.45 · 2023: $54.53 · 2024: $193 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $227.90 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $124.80 | 2025 | Zoryve |
| Kyowa Kirin, INC. | $121.86 | 2025 | |
| Genzyme Corporation | $116.15 | 2024 | |
| Gilead Sciences, INC. | $116.15 | 2025 | Epclusa |
| Cranial Technologies, INC | $106.92 | 2023-2025 | Doc Band |
| Seqirus USA INC | $67.10 | 2024-2025 | Flucelvax |
| Cipher Pharmaceuticals US LLC | $54.92 | 2025 | Spinosad, Natroba |
| Phadia US INC. | $40.59 | 2024-2025 | Immunocap |
| Merck Sharp & Dohme LLC | $24.44 | 2023 | Vaxneuvance, Vaqta, Gardasil 9 |
| Lnhc, INC | $23.19 | 2025 | Zelsuvmi |
| Pfizer INC. | $22.31 | 2025 | |
| Sanofi Pasteur INC. | $20.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigha Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.